BCL2 and acute myeloid leukemia: This review will outline the role of apoptotic pathways in promoting leukaemogenesis in AML, the development of BCL-2 inhibitors over time that has led to the recent approval of venetoclax by the FDA and ongoing trials targeting dysregulated apoptotic pathways in AML.